These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11830192)

  • 1. Immunotherapy for psoriasis: from serendipity to selectivity.
    Griffiths CE
    Lancet; 2002 Jan; 359(9303):279-80. PubMed ID: 11830192
    [No Abstract]   [Full Text] [Related]  

  • 2. Why do some biologic agents induce psoriasis or psoriasiform lesions?
    Laurindo IM; Scheinberg M
    Nat Clin Pract Rheumatol; 2008 Apr; 4(4):168-9. PubMed ID: 18253108
    [No Abstract]   [Full Text] [Related]  

  • 3. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker).
    Salim A; Emerson RM; Dalziel KL
    Br J Dermatol; 2000 Nov; 143(5):1121-2. PubMed ID: 11069550
    [No Abstract]   [Full Text] [Related]  

  • 5. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis but do not necessarily predict treatment failure.
    Golberg O; Osborne JE; Hutchinson PE
    Br J Dermatol; 2011 Feb; 164(2):459-60. PubMed ID: 20973773
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
    Girolomoni G; Abeni D
    Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
    [No Abstract]   [Full Text] [Related]  

  • 7. [Monoclonal antibodies targeting IL-17A or its receptor in psoriasis: a new therapeutic approach?].
    Bonnet MC; Bagot M; Bensussan A
    Med Sci (Paris); 2012 Dec; 28(12):1035-7. PubMed ID: 23290394
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-TNF-alpha-induced psoriasis: case report of an unusual adverse event.
    Aslanidis S; Pyrpasopoulou A; Leontsini M; Zamboulis C
    Int J Dermatol; 2006 Aug; 45(8):982-3. PubMed ID: 16911391
    [No Abstract]   [Full Text] [Related]  

  • 9. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
    Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
    Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy against psoriasis].
    Gjersvik PJ
    Tidsskr Nor Laegeforen; 2003 Apr; 123(8):1049. PubMed ID: 12760217
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Paradoxical" adverse effects caused by anti-tumor necrosis factor-α biological drugs: appearance of psoriasis in a patient treated with infliximab for rheumatoid arthritis.
    Satriano RA; Abbate G; Esposito S; Cassaglia B; Piccolo V; Baroni A
    Indian J Dermatol Venereol Leprol; 2011; 77(4):536. PubMed ID: 21727719
    [No Abstract]   [Full Text] [Related]  

  • 13. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
    Fleischmann R; Shealy D
    Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
    [No Abstract]   [Full Text] [Related]  

  • 14. Biology of tumor necrosis factor-alpha- implications for psoriasis.
    Schottelius AJ; Moldawer LL; Dinarello CA; Asadullah K; Sterry W; Edwards CK
    Exp Dermatol; 2004 Apr; 13(4):193-222. PubMed ID: 15086336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparing dermatology nurses: biologic therapy for psoriasis.
    Young MS
    Dermatol Nurs; 2003 Oct; 15(5):413-6, 419-23; quiz 424. PubMed ID: 14619318
    [No Abstract]   [Full Text] [Related]  

  • 16. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors.
    Meyer MW; Zachariae C; Bendtzen K; Skov L
    Acta Derm Venereol; 2012 Jul; 92(4):362-4. PubMed ID: 22864558
    [No Abstract]   [Full Text] [Related]  

  • 17. Current biologic treatments for psoriasis.
    Gottlieb AB; Kardos M; Yee M
    Dermatol Nurs; 2009; 21(5):259-66, 272; quiz 267. PubMed ID: 19873691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
    Mortel MR; Emer J
    J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmunity by anti-tumour necrosis factor-alpha agents: the role of traditional therapies.
    Antoniou C; Moustou AE; Vergou T; Stratigos A; Kalambokas A; Katsambas AD
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):356-7. PubMed ID: 19686257
    [No Abstract]   [Full Text] [Related]  

  • 20. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.